Hold Alkem Laboratories: Mayuresh Joshi

Mayuresh Joshi of Angel Broking told CNBC-TV18, "Being very selective at this point of time, specifically in the midcap names, so what we really liked was something like an Alkem Laboratories. What we have actually seen the kind of growth that you have seen both in terms of the prescription market share which is 38 odd percent and that is expected to even grow higher."

"Now if you are looking at the ANDA pipeline for this company for the US markets, 92 still in the pipeline and still a huge way to go. So, not affected in a large sense in terms of pricing pressures or any approvals there off. So, I think any approval front and significant earnings accretion from US Markets will aid the overall earnings."

"Our own sense is that a 10 percent topline growth and 13-14 percent bottom line growth is not ruled out. The stock has moved up significantly but any investors holding can definitely hold. A decline is something that I will put at in way of probably accumulating this stock. So we are very selective, I think Aurobindo Pharma and probably this stock Alkem Laboratories probably stay on our radar."